|
1
|
Xue YJ, Xiao RH, Long DZ, Zou XF, Wang XN,
Zhang GX, Yuan YH, Wu GQ, Yang J, Wu YT, et al: Overexpression of
FoxM1 is associated with tumor progression in patients with clear
cell renal cell carcinoma. J Transl Med. 10:2002012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mancuso A and Sternberg CN: New treatments
for metastatic kidney cancer. Can J Urol. 12(Suppl 1): S66–S70;
discussion 105. 2005.
|
|
3
|
Zisman A, Pantuck AJ, Wieder J, Chao DH,
Dorey F, Said JW, deKernion JB, Figlin RA and Belldegrun AS: Risk
group assessment and clinical outcome algorithm to predict the
natural history of patients with surgically resected renal cell
carcinoma. J Clin Oncol. 20:4559–4566. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cohen HT and McGovern FJ: Renal-cell
carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chambers AF, MacDonald IC, Schmidt EE,
Morris VL and Groom AC: Clinical targets for anti-metastasis
therapy. Adv Cancer Res. 79:91–121. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bracken CP, Gregory PA, Khew-Goodall Y and
Goodall GJ: The role of microRNAs in metastasis and
epithelial-mesenchymal transition. Cell Mol Life Sci. 66:1682–1699.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cakarovski K, Leung JY, Restall C,
Carin-Carlson A, Yang E, Perlmutter P, Anderson R, Medcalf R and
Dear AE: Novel inhibitors of urokinase-type plasminogen activator
and matrix metalloproteinase expression in metastatic cancer cell
lines. Int J Cancer. 110:610–616. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Toda D, Ota T, Tsukuda K, Watanabe K,
Fujiyama T, Murakami M, Naito M and Shimizu N: Gefitinib decreases
the synthesis of matrix metalloproteinase and the adhesion to
extracellular matrix proteins of colon cancer cells. Anticancer
Res. 26:129–134. 2006.PubMed/NCBI
|
|
9
|
Nelson AR, Fingleton B, Rothenberg ML and
Matrisian LM: Matrix metalloproteinases: Biologic activity and
clinical implications. J Clin Oncol. 18:1135–1149. 2000.PubMed/NCBI
|
|
10
|
Stoner GD and Mukhtar H: Polyphenols as
cancer chemopreventive agents. J Cell Biochem Suppl. 22:169–180.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Katiyar S and Mukhtar H: Tea in
chemoprevention of cancer. Int J Oncol. 8:221–238. 1996.PubMed/NCBI
|
|
12
|
Chen D, Wan SB, Yang H, Yuan J, Chan TH
and Dou QP: EGCG, green tea polyphenols and their synthetic analogs
and prodrugs for human cancer prevention and treatment. Adv Clin
Chem. 53:155–177. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Roomi MW, Monterrey JC, Kalinovsky T, Rath
M and Niedzwiecki A: Comparative effects of EGCG, green tea and a
nutrient mixture on the patterns of MMP-2 and MMP-9 expression in
cancer cell lines. Oncol Rep. 24:747–757. 2010.PubMed/NCBI
|
|
14
|
Lim YC, Park HY, Hwang HS, Kang SU, Pyun
JH, Lee MH, Choi EC and Kim CH: (−)-Epigallocatechin-3-gallate
(EGCG) inhibits HGF-induced invasion and metastasisin
hypopharyngeal carcinoma cells. Cancer Lett. 271:140–152. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Siddiqui IA, Malik A, Adhami VM, Asim M,
Hafeez BB, Sarfaraz S and Mukhtar H: Green tea polyphenol EGCG
sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated
apoptosis and synergistically inhibits biomarkers associated with
angiogenesis and metastasis. Oncogene. 27:2055–2063. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shankar S, Ganapathy S, Hingorani SR and
Srivastava RK: EGCG inhibits growth, invasion, angiogenesis and
metastasis of pancreatic cancer. Front Biosci. 13:440–452. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Volpe A and Patard JJ: Prognostic factors
in renal cell carcinoma. World J Urol. 28:319–327. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qiao HP, Gao WS, Huo JX and Yang ZS: Long
non-coding RNA GAS5 functions as a tumor suppressor in renal cell
carcinoma. Asian Pac J Cancer Prev. 14:1077–1082. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang L, Xul B, Chen S, Lu K, Liu C, Wang
Y, Zhao Y, Zhang X, Liu D and Chen M: The complex roles of
microRNAs in the metastasis of renal cell carcinoma. J Nanosci
Nanotechnol. 13:3195–3203. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Janzen NK, Kim HL, Figlin RA and
Belldegrun AS: Surveillance after radical or partial nephrectomy
for localized renal cell carcinoma and management of recurrent
disease. Urol Clin North Am. 30:843–852. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Waas ET, Wobbes T, Lomme RM, DeGroot J,
Ruers T and Hendriks T: Matrix metalloproteinase 2 and 9 activity
in patients with colorectal cancer liver metastasis. Br J Surg.
90:1556–1564. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang L, Shi J, Feng J, Klocker H, Lee C
and Zhang J: Type IV collagenase (matrix metalloproteinase-2 and
−9) in prostate cancer. Prostate Cancer Prostatic Dis. 7:327–332.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ma J, Fang B, Zeng F, Pang H, Zhang J, Shi
Y, Wu X, Cheng L, Ma C, Xia J and Wang Z: Curcumin inhibits cell
growth and invasion through up-regulation of miR-7 in pancreatic
cancer cells. Toxicol Lett. 231:82–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee HS, Ha AW and Kim WK: Effect of
resveratrol on the metastasis of 4T1 mouse reast cancer cells in
vitro and in vivo. Nutr Res Pract. 6:294–300. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim HJ, Kim SK, Kim BS, Lee SH, Park YS,
Park BK, Kim SJ, Kim J, Choi C and Kim JS: Apoptotic effect of
quercetin on HT-29 colon cancer cells via the AMPK signaling
pathway. J Agric Food Chem. 58:8643–8650. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Luo HQ, Xu M, Zhong WT, Cui ZY, Liu FM,
Zhou KY and Li XY: EGCG decreases the expression of HIF-1α and VEGF
and cell growth in MCF-7 breast cancer cells. J BUON. 19:435–439.
2014.PubMed/NCBI
|
|
27
|
Sakamoto Y, Terashita N, Muraguchi T,
Fukusato T and Kubota S: Effects of epigallocatechin-3-gallate
(EGCG) on A549 lung cancer tumor growth and angiogenesis. Biosci
Biotechnol Biochem. 77:1799–1803. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee JH, Jeong YJ, Lee SW, Kim D, Oh SJ,
Lim HS, Oh HK, Kim SH, Kim WJ and Jung JY: EGCG induces apoptosis
in human laryngeal epidermoid carcinoma Hep2 cells via mitochondria
with the release of apoptosis-inducing factor and endonuclease G.
Cancer Lett. 290:68–75. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chambers AF and Matrisian LM: Changing
views on the role of matrix metalloprotenases in metastasis. J Natl
Cancer Inst. 89:1260–1270. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kleiner DE and Stetler-Stevenson WG:
Matrix metalloproteinases and metastasis. Cancer Chemother
Pharmacol. 43(Suppl): S42–S51. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Deng YT and Lin JK: EGCG inhibits the
invasion of highly invasive CL1-5 lung cancer cells through
suppressing MMP-2 expression via JNK signaling and induces G2/M
arrest. J Agric Food Chem. 59:13318–13327. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sen T, Dutta A and Chatterjee A:
Epigallocatechin-3-gallate (EGCG) downregulates gelatinase-B
(MMP-9) by involvement of FAK/ERK/NFkappaB and AP-1 in the human
breast cancer cell line MDA-MB-231. Anticancer Drugs. 21:632–644.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim HS, Kim MH, Jeong M, Hwang YS, Lim SH,
Shin BA, Ahn BW and Jung YD: EGCG blocks tumor promoter-induced
MMP-9 expression via suppression of MAPK and AP-1 activation in
human gastric AGS cells. Anticancer Res. 24:747–753.
2004.PubMed/NCBI
|
